1 |
Scott AM, Wolchok JD and Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12, 278-287
DOI
ScienceOn
|
2 |
Liu JKH (2014) The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg 3, 113-116
DOI
|
3 |
Chames P, Van Regenmortel M, Weiss E and Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157, 220-233
DOI
ScienceOn
|
4 |
Tabrizi M, Bornstein GG and Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12, 33-43
DOI
|
5 |
Miller MJ, Foy KC and Kaumaya PT (2013) Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 15, 166-176
|
6 |
Jain RK and Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7, 653-664
DOI
|
7 |
Beckman RA, Weiner LM and Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179
DOI
ScienceOn
|
8 |
Sung HJ, Choi S, Lee JW et al (2014) Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8. Biomaterials 35, 578-589
DOI
ScienceOn
|
9 |
Kong HY and Byun J (2013) Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther 21, 423-434
DOI
ScienceOn
|
10 |
Kim YH, Sung HJ, Kim S et al (2011) An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett 313, 76-83
DOI
ScienceOn
|
11 |
Tuerk C and Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510
DOI
|
12 |
Keefe AD, Pai S and Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9, 537-550
DOI
ScienceOn
|
13 |
Sun H, Zhu X, Lu PY, Rosato RR, Tan W and Zu Y (2014) Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 3, e182
DOI
|
14 |
Dong Y, Xu Y, Yong W, Chu X and Wang D (2014) Aptamer and its potential applications for food safety. Crit Rev Food Sci Nutr 54, 1548-1561
DOI
|
15 |
Bates PJ, Laber DA, Miller DM, Thomas SD and Trent JO (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86, 151-164
DOI
ScienceOn
|
16 |
Song KM, Lee S and Ban C (2012) Aptamers and Their Biological Applications. Sensors (Basel) 12, 612-631
DOI
|
17 |
Tan W, Wang H, Chen Y et al (2011) Molecular aptamers for drug delivery. Trends Biotechnol 29, 634-640
DOI
ScienceOn
|
18 |
Pendergrast PS, Marsh HN, Grate D, Healy JM and Stanton M (2005) Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech 16, 224-234
|
19 |
Tajrishi MM, Tuteja R and Tuteja N (2011) Nucleolin: The most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol 4, 267-275
DOI
|
20 |
Nagasawa T, Hirota S, Tachibana K et al (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638
DOI
ScienceOn
|
21 |
Zhu J, Huang H, Dong S, Ge L and Zhang Y (2014) Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics 4, 931-944
DOI
ScienceOn
|
22 |
Laber DA, Sharma VR, Bhupalam L, Taft B, Hendler FJ and Barnhart KM (2005) Update on the first phase I study of AGRO100 in advanced cancer. J Clin Oncol 23, 3064
DOI
|
23 |
Ni X, Castanares M, Mukherjee A and Lupold SE (2011) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18, 4206-4214
DOI
|
24 |
Sun X, Cheng G, Hao M et al (2010) CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29, 709-722
DOI
|
25 |
Zhou J and Rossi JJ (2014) Cell-type-specific, Aptamerfunctionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids 3, e169
DOI
ScienceOn
|
26 |
Shum KT, Zhou J and Rossi JJ (2013) Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther 4, 872-890
DOI
|
27 |
Hoellenriegel J, Zboralski D, Maasch C et al (2014) The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123, 1032-1039
DOI
ScienceOn
|
28 |
Liu SC, Alomran R, Chernikova SB et al (2014) Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol 16, 21-28
DOI
ScienceOn
|
29 |
Bruno JG (2013) A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel) 6, 340-357
DOI
ScienceOn
|
30 |
McNamara JO, Andrechek ER, Wang Y et al (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24, 1005-1015
DOI
ScienceOn
|
31 |
Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA and Langer R (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64, 7668-7672
DOI
ScienceOn
|
32 |
Farokhzad OC, Cheng J, Teply BA et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103, 6315-6320
DOI
ScienceOn
|
33 |
Yu C, Hu Y, Duan J et al (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 6, e24077
DOI
|
34 |
Griffin LC, Tidmarsh GF, Bock LC, Toole JJ and Leung LL (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81, 3271-3276
|
35 |
Leal M, Sapra P, Hurvitz SA et al (2014) Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci 1321, 41-54
DOI
ScienceOn
|
36 |
Perez HL, Cardarelli PM, Deshpande S et al (2014) Antibody-drug conjugates: current status and future directions. Drug Discov Today 19, 869-881
DOI
ScienceOn
|
37 |
Shigdar S, Macdonald J, O'Connor M et al (2013) Aptamers as theranostic agents: modifications, serum stability and functionalisation. Sensors (Basel) 13, 13624-13637
DOI
|
38 |
Davydova AS, Vorobjeva MA and Venyaminova AG (2011) Escort aptamers: new tools for the targeted delivery of therapeutics into cells. Acta Naturae 3, 12-29
|
39 |
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR and Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5, 123-132
DOI
ScienceOn
|
40 |
Burmeister PE, Lewis SD, Silva RF et al (2005) Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem Biol 12, 25-33
DOI
ScienceOn
|
41 |
Lakhin AV, Tarantul VZ and Gening LV (2013) Aptamers: problems, solutions and prospects. Acta Naturae 5, 34-43
|
42 |
Healy JM, Lewis SD, Kurz M et al (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21, 2234-2246
DOI
|
43 |
Ruggiero A, Villa CH, Bander E et al (2010) Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 107, 12369-12374
DOI
ScienceOn
|
44 |
Kaiser PK, Cruess AF, Bogaert P, Khunti K and Kelly SP (2012) Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 250, 1563-1571
DOI
|
45 |
Shapiro A and Lafond A (2012) Anti-VEGF state of the union. Retina Today Jan/Feb, 32-34
|